Doripenem HydrateInjectable antibiotic,ultra-broad spectrum CAS# 364622-82-2 |
- Tigecycline mesylate
Catalog No.:BCC4229
CAS No.:1135871-27-0
- Amphotericin B
Catalog No.:BCN2564
CAS No.:1397-89-3
- Nystatin (Fungicidin)
Catalog No.:BCC4813
CAS No.:1400-61-9
- Tigecycline hydrochloride
Catalog No.:BCC4228
CAS No.:197654-04-9
- Toyocamycin
Catalog No.:BCC8047
CAS No.:606-58-6
- Norfloxacin hydrochloride
Catalog No.:BCC4230
CAS No.:68077-27-0
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 364622-82-2 | SDF | Download SDF |
| PubChem ID | 636377 | Appearance | Powder |
| Formula | C15H26N4O7S2 | M.Wt | 438.52 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | S 4661 monohydrate | ||
| Solubility | DMSO : 50 mg/mL (114.02 mM; Need ultrasonic) H2O : 10 mg/mL (22.80 mM; Need ultrasonic) | ||
| Chemical Name | (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;hydrate | ||
| SMILES | CC1C2C(C(=O)N2C(=C1SC3CC(NC3)CNS(=O)(=O)N)C(=O)O)C(C)O.O | ||
| Standard InChIKey | NTUBEBXBDGKBTJ-WGLOMNHJSA-N | ||
| Standard InChI | InChI=1S/C15H24N4O6S2.H2O/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25;/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25);1H2/t6-,7-,8+,9+,10-,11-;/m1./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Doripenem monohydrate is a new member of the carbapenem class of beta-lactam antibiotics with broad-spectrum coverage of Gram-positive, Gram-negative and anaerobic pathogens.
Target: Antibacterial
Doripenem is an ultra-broad-spectrum injectable antibiotic. It is a beta-lactam and belongs to the subgroup of carbapenems. It was launched by Shionogi Co. of Japan under the brand name Finibax in 2005 and is being marketed outside Japan by Johnson & Johnson. It is particularly active against Pseudomonas aeruginosa. It is recommended that those allergic to doripenem or to any type of beta-lactam antibiotics such as cephalosporin or other Carbapenems not receive doripenem.
Doripenem appears as crystalline powder anywhere from a white to somewhat yellowish colour.Doripenem is moderately soluble in water, slightly soluble in methanol, and virtually insoluble in ethanol. Doripenem is also solution in N,N-dimethylformamide. Doripenem's chemical configuration has 6 asymmetrical carbon atoms (6 stereocentres) and is most commonly supplied as one pure isomer. In terms of doripenem for injection, the crystallized powered drug can form a monohydrate when mixed with water. However, Doripenem has not been proven to possess polymorphism. References: | |||||
Doripenem Hydrate Dilution Calculator
Doripenem Hydrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2804 mL | 11.402 mL | 22.804 mL | 45.608 mL | 57.0099 mL |
| 5 mM | 0.4561 mL | 2.2804 mL | 4.5608 mL | 9.1216 mL | 11.402 mL |
| 10 mM | 0.228 mL | 1.1402 mL | 2.2804 mL | 4.5608 mL | 5.701 mL |
| 50 mM | 0.0456 mL | 0.228 mL | 0.4561 mL | 0.9122 mL | 1.1402 mL |
| 100 mM | 0.0228 mL | 0.114 mL | 0.228 mL | 0.4561 mL | 0.5701 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Doripenem hydrate is a parenteral, potent, and well-balanced antibiotic against a wide range of both Gram+ and Gram- bacteria including Pseudomonas aeruginosa [1] with MIC90 values of ≤ 0.5 µg/ml against methicillin-susceptible streptococci and staphylococci, 0.032-0.5 µg/ml against members of the family Enterobacteriaceae, Moraxella catarrhalis, and Haemophilus influenza, and 8 µg/ml against Pseudomonas aeruginosa [2].
Patients with cystic fibrosis can be infected with several pathogens such as Haemophilus influenzae, Staphylococcus aureus and P. aeruginosa, chronically. By 18 years of age, 80% of cystic fibrosis patients are infected with P. aeruginosa [3].
Doripenem hydrate was potent against Staphylococcus aureus and Staphylococcus epidermidis with the same MIC90 value of 0.063 µg/ml. Doripenem hydrate was 2-4 times more active than other tested carbapenems against S. aureus. The activity of doripenem hydrate against S. pneumoniae was similar to that of imipenem but higher than that of other tested agents. Doripenem hydrate was potent against S. pneumonia with an activity similar to that of other tested carbapenems (MIC90, 0.5 µg/ml). Doripenem hydrate had an activity similar to that of cefpirome against S. pneumoniae and S. pyogenes. Doripenem hydrate was more active against Enterococcus faecalis than other tested agents except for imipenem [2].
In mice experimentally induced with acute bacteremia, the ED50 of doripenem hydrate against S. aureus Smith was 0.066 mg/kg. Doripenem hydrate was more effective than other tested carbapenems against S. aureus TUH1. Doripenem hydrate was more effective than other tested agents except for meropenem-cilastatin against E. coli C-11. Doripenem hydrate almost shared the same effectiveness with other tested carbapenems against P. aeruginosa E7. Against P. aeruginosa TUH302, doripenem hydrate was the most effective among tested drugs [2].
References:
[1]. Yutaka Nishino, Makoto Kobayashi, Taneyoshi Shinno, et al. Practical Large-Scale Synthesis of Doripenem: A Novel 1â-Methylcarbapenem Antibiotic. Organic Process Research & Development, 2003, 7:846-850.
[2]. Masakatsu Tsuji, Yoshikazu Ishii, Akira Ohno, et al. In Vitro and In Vivo Antibacterial Activities of S-4661, a New Carbapenem. Antimicrobial Agents and Chemotherapy, 1998, 42(1): 94-99.
[3]. Yunhua Chen, Elizabeth Garber, Qiuqu Zhao, et al. In Vitro Activity of Doripenem (S-4661) against Multidrug-Resistant Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2005, 49(6):2510-2511.
- Lucidenic acid SP1
Catalog No.:BCN7969
CAS No.:364622-33-3
- 6beta-Hydroxystigmast-4-en-3-one
Catalog No.:BCN5322
CAS No.:36450-02-9
- 6-Hydroxystigmasta-4,22-dien-3-one
Catalog No.:BCN5321
CAS No.:36450-01-8
- Tolperisone HCl
Catalog No.:BCC4740
CAS No.:3644-61-9
- N-p-trans-Coumaroyltyramine
Catalog No.:BCN5320
CAS No.:36417-86-4
- A 419259
Catalog No.:BCC4307
CAS No.:364042-47-7
- Diazoxide
Catalog No.:BCC6868
CAS No.:364-98-7
- Metoclopramide
Catalog No.:BCC1743
CAS No.:364-62-5
- α,α'-Bis(4-hydroxy-3,5-dimethylphenyl)-1,4-diisopropylbenzene
Catalog No.:BCC9196
CAS No.:36395-57-0
- 4-Methylhistamine dihydrochloride
Catalog No.:BCC7337
CAS No.:36376-47-3
- Oxyphyllenone A
Catalog No.:BCN7103
CAS No.:363610-34-8
- Cyclo(L-Ala-L-Pro)
Catalog No.:BCN4012
CAS No.:36357-32-1
- Ginsenoside Rk2
Catalog No.:BCN3721
CAS No.:364779-14-6
- Ginsenoside Rk3
Catalog No.:BCN3502
CAS No.:364779-15-7
- Cinacalcet HCl
Catalog No.:BCC4408
CAS No.:364782-34-3
- Methylsynephrine Hydrochloride
Catalog No.:BCN3407
CAS No.:365-26-4
- Carnosic acid
Catalog No.:BCN5892
CAS No.:3650-09-7
- Agatholal
Catalog No.:BCN5323
CAS No.:3650-31-5
- beta-Costic acid
Catalog No.:BCN5324
CAS No.:3650-43-9
- Emiline
Catalog No.:BCN2080
CAS No.:36506-99-7
- Serpentinine
Catalog No.:BCN5325
CAS No.:36519-42-3
- Guaiacin
Catalog No.:BCN4127
CAS No.:36531-08-5
- Cycloheterophyllin
Catalog No.:BCN4640
CAS No.:36545-53-6
- Ac-Tyr-OEt.H2O
Catalog No.:BCC3121
CAS No.:36546-50-6
[A case of probable catastrophic antiphospholipid syndrome with multi-organ failure presenting as a transient increase of antiphospholipid antibody levels].[Pubmed:24974932]
Nihon Rinsho Meneki Gakkai Kaishi. 2014;37(3):183-8.
A 44-year-old woman was admitted to our hospital with shock, massive pneumonia and respiratory failure, liver and renal dysfunction, and cerebral infarction. Based on these symptoms, we suspected the presence of disseminated intravascular coagulation and multiple organ dysfunctions due to massive pneumonia or catastrophic antiphospholipid syndrome (CAPS). Therefore, the patient was placed on a respirator and was administered ciprofloxacin, Doripenem Hydrate, thrombomodulin, antithrombin III, and methylprednisolone pulse therapy. Because the patient's antiphospholipid antibody titer was low on the day of admission (day 1), we did not include CAPS in the differential diagnosis and discontinued prednisolone treatment on day 6. However, the anticardiolipin immunoglobulin M antibody titer was found to be elevated on day 7; in addition, a transient increase in the anticardiolipin anti-beta2 glycoprotein antibody titer was noted on re-examination. Moreover, on day 8, the thrombopenia and alveolar hemorrhage suddenly exacerbated. We finally diagnosed the patient with CAPS, and therefore resumed methylprednisolone therapy. Subsequently, the inflammation, respiratory failure, and thrombopenia rapidly improved, and the patient was extubated on day 12.
Gateways to clinical trials.[Pubmed:19798455]
Methods Find Exp Clin Pharmacol. 2009 Jul-Aug;31(6):397-417.
[90Y-DOTA-Tyr3]octreotate, Abatacept, ABT-888, ACE-011, Adefovir dipivoxil, Alosetron hydrochloride, Aminolevulinic acid methyl ester, Amlodipine, Apaziquone, Aripiprazole, AS-101, Atomoxetine hydrochloride, Atrasentan, Azacitidine; Bevacizumab, Biphasic insulin aspart, Bortezomib, Bosentan, Brivanib alaninate; CERE-120, Cetuximab, Ciclesonide, Cinacalcet hydrochloride, Combretastatin A-1 phosphate, Conatumumab, CT-322; Dabigatran etexilate, Darunavir, Deforolimus, Desloratadine, Doripenem, Doxorubicin eluting beads, Duloxetine hydrochloride, Dutasteride; Escitalopram oxalate, Eszopiclone, Etravirine, Exenatide, Ezetimibe, Ezetimibe/simvastatin; Fluticasone furoate, Fondaparinux sodium; Gabapentin enacarbil, Ghrelin (human), Golimumab; IC-51, IDM-2, JX-594; Lidocaine/prilocaine, Liraglutide, Lopinavir, Lopinavir/ritonavir, Lumiracoxib; Men ACWY, MxdnG1; Naproxcinod; OBP-301, Omalizumab; Paclitaxel nanoparticles, Pasireotide, Pazopanib hydrochloride, Pegaptanib octasodium, Peginterferon alfa-2a, Pegvisomant, Pemetrexed disodium, Pimecrolimus, Prasterone, Pregabalin; Raclopride, Ranelic acid distrontium salt, Ranibizumab, RB-006, Recombinant human relaxin H2, REG1, Regadenoson, Reximmune-C, Rilonacept; Saxagliptin, SCH-697243, Solifenacin succinate, Sorafenib; Tadalafil, Tapentadol hydrochloride, Tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate/emtricitabine, Tipifarnib, Tolvaptan; Vardenafil hydrochloride hydrate, Vicriviroc, Volociximab, Vorinostat; WB-1001; Yttrium 90 (90Y) ibritumomab tiuxetan.
